Cargando…
The serological prevalence of SARS‐CoV‐2 infection in patients with chronic myeloid leukemia is similar to that in the general population
BACKGROUND: Patients with hematological malignancies are at an increased risk of SARS‐CoV‐2 disease (COVID‐19) and adverse outcome. However, a low mortality rate has been reported in patients with chronic myeloid leukemia (CML). Preclinical evidence suggests that tyrosine kinase inhibitors (TKIs) ma...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8446554/ https://www.ncbi.nlm.nih.gov/pubmed/34464516 http://dx.doi.org/10.1002/cam4.4179 |
_version_ | 1784568905443835904 |
---|---|
author | Bonifacio, Massimiliano Tiribelli, Mario Miggiano, Maria Cristina Abruzzese, Elisabetta Binotto, Gianni Scaffidi, Luigi Cordioli, Maddalena Damiani, Daniela Di Bona, Eros Trawinska, Malgorzata Monika Tanasi, Ilaria Dubbini, Maria Vittoria Velotta, Vanessa Ceccarelli, Giulia Pierdomenico, Elisabetta Lo Schirico, Mariella Semenzato, Gianpietro Ruggeri, Marco Fanin, Renato Tacconelli, Evelina Pizzolo, Giovanni Krampera, Mauro |
author_facet | Bonifacio, Massimiliano Tiribelli, Mario Miggiano, Maria Cristina Abruzzese, Elisabetta Binotto, Gianni Scaffidi, Luigi Cordioli, Maddalena Damiani, Daniela Di Bona, Eros Trawinska, Malgorzata Monika Tanasi, Ilaria Dubbini, Maria Vittoria Velotta, Vanessa Ceccarelli, Giulia Pierdomenico, Elisabetta Lo Schirico, Mariella Semenzato, Gianpietro Ruggeri, Marco Fanin, Renato Tacconelli, Evelina Pizzolo, Giovanni Krampera, Mauro |
author_sort | Bonifacio, Massimiliano |
collection | PubMed |
description | BACKGROUND: Patients with hematological malignancies are at an increased risk of SARS‐CoV‐2 disease (COVID‐19) and adverse outcome. However, a low mortality rate has been reported in patients with chronic myeloid leukemia (CML). Preclinical evidence suggests that tyrosine kinase inhibitors (TKIs) may have a protective role against severe COVID‐19. METHODS: We conducted a cross‐sectional study of 564 consecutive patients with CML who were tested for anti‐SARS‐CoV‐2 IgG/IgM antibodies at their first outpatient visit between May and early November 2020 in five hematologic centers representative of three Italian regions. RESULTS: The estimated serological prevalence of SARS‐CoV‐2 infection in patients with CML after the first pandemic wave was similar to that in the general population (about 2%), both at national and regional levels. CML patients with positive anti‐SARS‐CoV‐2 serology were more frequently male (p = 0.027) and active workers (p = 0.012), while there was no significant association with TKI treatment type. Only 3 out of 11 IgG‐positive patients had previously received a molecular diagnosis of COVID‐19, while the remainders were asymptomatic or with mild symptoms. CONCLUSIONS: Our data confirm that the course of SARS‐CoV‐2 infection in patients with CML is generally mild and reassure about the safety of continuing TKIs during the COVID‐19 pandemic. Furthermore, we suggest that patients with CML succeed to mount an antibody response after exposure to SARS‐CoV‐2, similar to the general population. |
format | Online Article Text |
id | pubmed-8446554 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84465542021-09-22 The serological prevalence of SARS‐CoV‐2 infection in patients with chronic myeloid leukemia is similar to that in the general population Bonifacio, Massimiliano Tiribelli, Mario Miggiano, Maria Cristina Abruzzese, Elisabetta Binotto, Gianni Scaffidi, Luigi Cordioli, Maddalena Damiani, Daniela Di Bona, Eros Trawinska, Malgorzata Monika Tanasi, Ilaria Dubbini, Maria Vittoria Velotta, Vanessa Ceccarelli, Giulia Pierdomenico, Elisabetta Lo Schirico, Mariella Semenzato, Gianpietro Ruggeri, Marco Fanin, Renato Tacconelli, Evelina Pizzolo, Giovanni Krampera, Mauro Cancer Med Clinical Cancer Research BACKGROUND: Patients with hematological malignancies are at an increased risk of SARS‐CoV‐2 disease (COVID‐19) and adverse outcome. However, a low mortality rate has been reported in patients with chronic myeloid leukemia (CML). Preclinical evidence suggests that tyrosine kinase inhibitors (TKIs) may have a protective role against severe COVID‐19. METHODS: We conducted a cross‐sectional study of 564 consecutive patients with CML who were tested for anti‐SARS‐CoV‐2 IgG/IgM antibodies at their first outpatient visit between May and early November 2020 in five hematologic centers representative of three Italian regions. RESULTS: The estimated serological prevalence of SARS‐CoV‐2 infection in patients with CML after the first pandemic wave was similar to that in the general population (about 2%), both at national and regional levels. CML patients with positive anti‐SARS‐CoV‐2 serology were more frequently male (p = 0.027) and active workers (p = 0.012), while there was no significant association with TKI treatment type. Only 3 out of 11 IgG‐positive patients had previously received a molecular diagnosis of COVID‐19, while the remainders were asymptomatic or with mild symptoms. CONCLUSIONS: Our data confirm that the course of SARS‐CoV‐2 infection in patients with CML is generally mild and reassure about the safety of continuing TKIs during the COVID‐19 pandemic. Furthermore, we suggest that patients with CML succeed to mount an antibody response after exposure to SARS‐CoV‐2, similar to the general population. John Wiley and Sons Inc. 2021-08-31 /pmc/articles/PMC8446554/ /pubmed/34464516 http://dx.doi.org/10.1002/cam4.4179 Text en © 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Cancer Research Bonifacio, Massimiliano Tiribelli, Mario Miggiano, Maria Cristina Abruzzese, Elisabetta Binotto, Gianni Scaffidi, Luigi Cordioli, Maddalena Damiani, Daniela Di Bona, Eros Trawinska, Malgorzata Monika Tanasi, Ilaria Dubbini, Maria Vittoria Velotta, Vanessa Ceccarelli, Giulia Pierdomenico, Elisabetta Lo Schirico, Mariella Semenzato, Gianpietro Ruggeri, Marco Fanin, Renato Tacconelli, Evelina Pizzolo, Giovanni Krampera, Mauro The serological prevalence of SARS‐CoV‐2 infection in patients with chronic myeloid leukemia is similar to that in the general population |
title | The serological prevalence of SARS‐CoV‐2 infection in patients with chronic myeloid leukemia is similar to that in the general population |
title_full | The serological prevalence of SARS‐CoV‐2 infection in patients with chronic myeloid leukemia is similar to that in the general population |
title_fullStr | The serological prevalence of SARS‐CoV‐2 infection in patients with chronic myeloid leukemia is similar to that in the general population |
title_full_unstemmed | The serological prevalence of SARS‐CoV‐2 infection in patients with chronic myeloid leukemia is similar to that in the general population |
title_short | The serological prevalence of SARS‐CoV‐2 infection in patients with chronic myeloid leukemia is similar to that in the general population |
title_sort | serological prevalence of sars‐cov‐2 infection in patients with chronic myeloid leukemia is similar to that in the general population |
topic | Clinical Cancer Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8446554/ https://www.ncbi.nlm.nih.gov/pubmed/34464516 http://dx.doi.org/10.1002/cam4.4179 |
work_keys_str_mv | AT bonifaciomassimiliano theserologicalprevalenceofsarscov2infectioninpatientswithchronicmyeloidleukemiaissimilartothatinthegeneralpopulation AT tiribellimario theserologicalprevalenceofsarscov2infectioninpatientswithchronicmyeloidleukemiaissimilartothatinthegeneralpopulation AT miggianomariacristina theserologicalprevalenceofsarscov2infectioninpatientswithchronicmyeloidleukemiaissimilartothatinthegeneralpopulation AT abruzzeseelisabetta theserologicalprevalenceofsarscov2infectioninpatientswithchronicmyeloidleukemiaissimilartothatinthegeneralpopulation AT binottogianni theserologicalprevalenceofsarscov2infectioninpatientswithchronicmyeloidleukemiaissimilartothatinthegeneralpopulation AT scaffidiluigi theserologicalprevalenceofsarscov2infectioninpatientswithchronicmyeloidleukemiaissimilartothatinthegeneralpopulation AT cordiolimaddalena theserologicalprevalenceofsarscov2infectioninpatientswithchronicmyeloidleukemiaissimilartothatinthegeneralpopulation AT damianidaniela theserologicalprevalenceofsarscov2infectioninpatientswithchronicmyeloidleukemiaissimilartothatinthegeneralpopulation AT dibonaeros theserologicalprevalenceofsarscov2infectioninpatientswithchronicmyeloidleukemiaissimilartothatinthegeneralpopulation AT trawinskamalgorzatamonika theserologicalprevalenceofsarscov2infectioninpatientswithchronicmyeloidleukemiaissimilartothatinthegeneralpopulation AT tanasiilaria theserologicalprevalenceofsarscov2infectioninpatientswithchronicmyeloidleukemiaissimilartothatinthegeneralpopulation AT dubbinimariavittoria theserologicalprevalenceofsarscov2infectioninpatientswithchronicmyeloidleukemiaissimilartothatinthegeneralpopulation AT velottavanessa theserologicalprevalenceofsarscov2infectioninpatientswithchronicmyeloidleukemiaissimilartothatinthegeneralpopulation AT ceccarelligiulia theserologicalprevalenceofsarscov2infectioninpatientswithchronicmyeloidleukemiaissimilartothatinthegeneralpopulation AT pierdomenicoelisabetta theserologicalprevalenceofsarscov2infectioninpatientswithchronicmyeloidleukemiaissimilartothatinthegeneralpopulation AT loschiricomariella theserologicalprevalenceofsarscov2infectioninpatientswithchronicmyeloidleukemiaissimilartothatinthegeneralpopulation AT semenzatogianpietro theserologicalprevalenceofsarscov2infectioninpatientswithchronicmyeloidleukemiaissimilartothatinthegeneralpopulation AT ruggerimarco theserologicalprevalenceofsarscov2infectioninpatientswithchronicmyeloidleukemiaissimilartothatinthegeneralpopulation AT faninrenato theserologicalprevalenceofsarscov2infectioninpatientswithchronicmyeloidleukemiaissimilartothatinthegeneralpopulation AT tacconellievelina theserologicalprevalenceofsarscov2infectioninpatientswithchronicmyeloidleukemiaissimilartothatinthegeneralpopulation AT pizzologiovanni theserologicalprevalenceofsarscov2infectioninpatientswithchronicmyeloidleukemiaissimilartothatinthegeneralpopulation AT kramperamauro theserologicalprevalenceofsarscov2infectioninpatientswithchronicmyeloidleukemiaissimilartothatinthegeneralpopulation AT bonifaciomassimiliano serologicalprevalenceofsarscov2infectioninpatientswithchronicmyeloidleukemiaissimilartothatinthegeneralpopulation AT tiribellimario serologicalprevalenceofsarscov2infectioninpatientswithchronicmyeloidleukemiaissimilartothatinthegeneralpopulation AT miggianomariacristina serologicalprevalenceofsarscov2infectioninpatientswithchronicmyeloidleukemiaissimilartothatinthegeneralpopulation AT abruzzeseelisabetta serologicalprevalenceofsarscov2infectioninpatientswithchronicmyeloidleukemiaissimilartothatinthegeneralpopulation AT binottogianni serologicalprevalenceofsarscov2infectioninpatientswithchronicmyeloidleukemiaissimilartothatinthegeneralpopulation AT scaffidiluigi serologicalprevalenceofsarscov2infectioninpatientswithchronicmyeloidleukemiaissimilartothatinthegeneralpopulation AT cordiolimaddalena serologicalprevalenceofsarscov2infectioninpatientswithchronicmyeloidleukemiaissimilartothatinthegeneralpopulation AT damianidaniela serologicalprevalenceofsarscov2infectioninpatientswithchronicmyeloidleukemiaissimilartothatinthegeneralpopulation AT dibonaeros serologicalprevalenceofsarscov2infectioninpatientswithchronicmyeloidleukemiaissimilartothatinthegeneralpopulation AT trawinskamalgorzatamonika serologicalprevalenceofsarscov2infectioninpatientswithchronicmyeloidleukemiaissimilartothatinthegeneralpopulation AT tanasiilaria serologicalprevalenceofsarscov2infectioninpatientswithchronicmyeloidleukemiaissimilartothatinthegeneralpopulation AT dubbinimariavittoria serologicalprevalenceofsarscov2infectioninpatientswithchronicmyeloidleukemiaissimilartothatinthegeneralpopulation AT velottavanessa serologicalprevalenceofsarscov2infectioninpatientswithchronicmyeloidleukemiaissimilartothatinthegeneralpopulation AT ceccarelligiulia serologicalprevalenceofsarscov2infectioninpatientswithchronicmyeloidleukemiaissimilartothatinthegeneralpopulation AT pierdomenicoelisabetta serologicalprevalenceofsarscov2infectioninpatientswithchronicmyeloidleukemiaissimilartothatinthegeneralpopulation AT loschiricomariella serologicalprevalenceofsarscov2infectioninpatientswithchronicmyeloidleukemiaissimilartothatinthegeneralpopulation AT semenzatogianpietro serologicalprevalenceofsarscov2infectioninpatientswithchronicmyeloidleukemiaissimilartothatinthegeneralpopulation AT ruggerimarco serologicalprevalenceofsarscov2infectioninpatientswithchronicmyeloidleukemiaissimilartothatinthegeneralpopulation AT faninrenato serologicalprevalenceofsarscov2infectioninpatientswithchronicmyeloidleukemiaissimilartothatinthegeneralpopulation AT tacconellievelina serologicalprevalenceofsarscov2infectioninpatientswithchronicmyeloidleukemiaissimilartothatinthegeneralpopulation AT pizzologiovanni serologicalprevalenceofsarscov2infectioninpatientswithchronicmyeloidleukemiaissimilartothatinthegeneralpopulation AT kramperamauro serologicalprevalenceofsarscov2infectioninpatientswithchronicmyeloidleukemiaissimilartothatinthegeneralpopulation |